Roche gives up on anticipated ‘good cholesterol’ drug

Roche's ($RHHBY) once-promising "good cholesterol" drug candidate is now history. The Swiss company stopped development of dalcetrapib after it fell short in a late-stage trial. Coupled with the failu…
Read the full story: News